|Year : 2015 | Volume
| Issue : 6 | Page : 537-543
Prachi A Bhattar1, Vijay P Zawar2, Kiran V Godse1, Sharmila P Patil1, Nitin J Nadkarni1, Manjyot M Gautam1
1 Department of Dermatology, Dr. D. Y. Patil Hospital and Research Institute, Nerul, Navi Mumbai, India
2 Skin Diseases Centre, Nashik, Maharashtra, India
|Date of Web Publication||5-Nov-2015|
Prachi A Bhattar
Department of Dermatology, Dr. D. Y. Patil Hospital and Research Institute, Sector 5, Nerul, Navi Mumbai 400 706, Maharashtra
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Exogenous ochronosis (EO) is a cutaneous disorder characterized by blue-black pigmentation resulting as a complication of long-term application of skin-lightening creams containing hydroquinone but may also occur due to topical contact with phenol or resorcinol in dark-skinned individuals. It can also occur following the use of systemic antimalarials such as quinine. EO is clinically and histologically similar to its endogenous counterpart viz., alkaptonuria, which, however, exhibits systemic effects and is an inherited disorder. Dermoscopy and in vivo skin reflectance confocal microscopy are noninvasive in vivo diagnostic tools. It is very difficult to treat EO, a cosmetically disfiguring and troubling disorder with disappointing treatment options.
Keywords: Exogenous ochronosis, hydroquinone, melasma
|How to cite this article:|
Bhattar PA, Zawar VP, Godse KV, Patil SP, Nadkarni NJ, Gautam MM. Exogenous Ochronosis. Indian J Dermatol 2015;60:537-43
What was known?
EO is an under diagnosed and frequently missed condition in clinical practice. A high degree of suspicion is necessary to recognize this condition.
| Introduction|| |
The term ochronosis is derived from the word "ochre" in Greek language, which refers to yellow discoloration. 
Ochronosis is an uncommon disorder characterized by a clinical appearance of blue-black or gray-blue pigmentation, which reflects the histological finding of yellow-brown deposits in the dermis.  It most commonly affects the skin and sometimes the cartilages of ears and sclera of eyes.
There are two types of ochronosis:
- Endogenous that is, alkaptonuric ochronosis
- Exogenous ochronosis (EO)
EO also called alkaptonuria or "black urine disease" is an inherited autosomal recessive disorder caused by a defect mapped on chromosome 4q23 that renders the enzyme homogentisate 1,2 dioxygenase inactive. This leads to the accumulation of homogentisic acid (1,2-dihydroxyphenolacetic acid, HGA) in the liver. HGA is a colorless phenolic acid that is soluble in water that accumulates in blood and is polymerized into brownish-black pigments which accumulate in connective tissues. HGA binds irreversibly to dermal fibrillar collagen which is said to be responsible for skin pigmentation, cardiopathy and/or arthropathy. It is characterized by predominant musculoskeletal manifestations. Extra-articular involvement is in the form of ocular symptoms, skin pigmentation, cardiac involvement, and genitourinary system involvement. ,,,,, In the urine, HGA is oxidized by the oxygen in the air into benzoquinone acetate (BQA). Urine is normal in color when freshly passed, but on exposure to air BQA rapidly darkens urine to assume brownish-black color. Alkalinization of the urine increases the rate of oxidation. It reduces cupric oxide and also silver nitrate solution. ,,,,, This forms the basis of an important bedside screening test which will differentiate alkaptonuria from EO. 
EO is an acquired condition and is clinically and histologically similar to alkaptonuria. It has no systemic manifestations. It presents as asymptomatic bilaterally symmetrical speckled blue-black macules and several gray-brown macules, previously described as "caviar-like" bodies, typically affecting the malar areas, temples, lower cheeks, and neck. Papular and nodular lesions may also be seen. It most commonly results from the use of topical hydroquinones (usually used as bleaching creams) but has also been associated with the use of phenol, quinine injection, resorcinol, picric acid, mercury, and oral antimalarials. ,,,
| History|| |
The term ochronosis was described by Virchow in 1866,  referring to a brownish-yellow pigment (ochre), that was deposited in the connective tissue of various organs. EO was first described in 1906 by Pick.  In 1912, Beddard and Plumtre,  described the disease when a patient used phenol for the treatment of an ulcer on the leg. In 1975, Findlay and De Beer  described EO in patients that used topical lightening agents containing hydroquinone.
| Epidemiology|| |
The global scenario
The exact incidence of EO is not known. The worldwide incidence has been assumed to be low.
There were many early reports on EO mainly from South Africa. In fact, the largest series of cases was from South Africa. ,,,, EO was described in 28-35% of black population. It was then thought that the condition is reported exclusively among dark-skinned African individuals. However, recently published reports show that the condition is also seen in many fair-skinned individuals such as Europeans and Hispanics. , The condition is reported correspondingly low in the USA. 
The exact epidemiological figures are not available except for the US, which mentions an incidence of 22 cases in more than 50 years. 
The clinical diagnosis may be missed in early stages where it may mimic melasma. The diagnosis may not be confirmed in a number of patients due to lack of skin biopsy findings. This might have led to under-reporting of the cases of EO. Thus, the actual incidence of EO might be much higher than that reflected in the global literature.
The Asian scenario
The incidence is said to be low in Asians, but cases are increasingly being reported from India, ,,, China,  Thailand,  Singapore. , In a recent case series from Singapore, Tan described 15 new cases in 5 year duration.  This indicates that EO may occur across a wide spectrum of skin types, from type II or III  to type V, and thus, is not limited to darker skin types. Recent increasing reports might be due to increased awareness of the condition.
The Indian scenario
First case of EO was reported by Zawar and Mhaskar  from Maharashtra, India (and possibly from South-East Asia) in 2004 in a female farmer, who developed EO after unsupervised application of 4% hydroquinone-containing preparation for more than 3 months for melasma. Subsequently, few more case reports from other parts of India have emerged on PubMed described by Gandhi et al.  and Jain et al.  Gandhi et al. reported a case of 50-year-old women who developed EO 2-5% of hydroquinone for a prolonged duration. A similar case of EO was reported by Jain et al. in which patient developed EO on the prolonged application of triple combination de-pigmentating agents. In all these reports, unsupervised usage of skin-lightening agents was a common highlighting feature.
| Etiology and Predisposing Factors|| |
Various factors necessary for the development of EO are unprotected prolonged sun-exposure, prolonged use of skin-lightening agents mainly containing hydroquinone and, presence of a number of viable melanocytes, as suggested by Hull and Procter.  Outdoor occupation, application of hydroquinone over a larger area or whole body and/or applying hydroquinone in large quantity may also predispose to this condition.
EO has been reported following long-term application of skin-lightening creams which contains hydroquinone, phenol or resorcinol. Of these, hydroquinone has the strongest association and was described by Findlay et al.  in 1975. The condition is due to continual use of hydroquinone, generally, in higher concentrations more than 2%. An alcoholic solution containing hydroquinone preparations are said to more readily predispose to EO than creams. 
Some of the recent reports mention the occurrence of EO even with as low concentrations of hydroquinone as 2%. 
The lesions may develop gradually over 6 months to 3 years or longer.  Two recent case reports from India mention the occurrence of EO with use of 2% hydroquinone preparations for 7-8 years. ,, All these reports, unsupervised usage of skin-lightening agents containing hydroquinone was a common highlighting feature.
| Pathogenesis|| |
The exact pathogenesis of EO is not known. Hydroquinone interferes with skin pigmentation by inhibiting tyrosinase enzyme thereby blocking the synthesis of melanin. It also inhibits synthesis of DNA and RNA.  Various theories put forth are speculative to explain the pathogenesis of EO. Findlay et al.  suggested that with prolonged use, hydroquinone passes down in the papillary dermis where the drug is engulfed by the fibroblasts. This leads to attachment of phenolic degradation products and subsequent polymerization of in collagen and elastic fibers. Sun exposure and thorough inunction of the topical preparations were said to result in more advanced changes. 
In 1983, Cullison et al.  theorized that hydroquinone is oxidized to quinine and forms hydroxylated indoles which is similar to melanin precursors.
In 1984, Engasser  believed that hydroquinone in higher concentrations stimulates melanocytes thereby producing more melanin.
However, the most accepted theory till date for the pathogenesis of EO was put forth by Penneys  stating that the hyper-pigmentation is due to local competitive inhibition of the enzyme homogentisic oxidase by hydroquinone, which leads to local accumulation of homogentisic acid and its metabolic products that polymerizes to form the so-called typical ochronotic pigment in the papillary dermis [Flow diagram 1].
| Clinical Features|| |
EO manifests as hyper-pigmentation in the photo-exposed regions.  It occurs over osseous surfaces  often affecting the zygomatic , regions in a symmetrical pattern. The lesions are gray-brown or blue-black macules usually with hyperchromic, pinpoint, and caviar-like papules  [Figure 1], [Figure 2], [Figure 3].
|Figure 3: Lesion showing caviar-like papules and reticulate pigmentation|
Click here to view
The most initial clinical classification was suggested in 1979 by Dogliotti and Leibowitz.  They described EO in three clinical stages as follows:
Stage I - Erythema and mild hyper-pigmentation: This stage might be clinically indistinguishable from melasma [Figure 2]
Stage II - Progressive hyper-pigmentation pigmented colloid milium (caviar-like lesions) and scanty atrophy
Stage III - Papulonodular (sarcoid-like) lesions.
In 1986, Phillips et al.  graded and described the condition as:
Mild - Coarsening and darkening of the skin
Moderate - Large black papules; skin in between papules is of normal pigmentation
Severe - Larger, coalescing, caviar-like papules, which are relatively dark in color.
In 1989, Hardwick et al.  in their epidemiological study based on clinical diagnosis graded EO as:
Grade I - Faint macular sooty pigmentation
Grade II - Distinct macular stippling/small papules
Grade III - Dark deposits and papules
Grade IV - Colloid milia (1 mm and greater) [Figure 4]
Grade V - Keloid-like nodules and cysts.
In 1991, Jordaan and Van Niekerk  described two extremes of EO. The milder variant characterized by coarsening and darkening of skin and the severe one with caviar-like black papules and skin atrophy.
| Diagnosis|| |
Most of the diagnostic dilemma arises when EO presents in early stages in Asian and ethnic Chinese individuals where it is taken as melasma, and then treated with hydroquinone-containing products, thus leads to further aggravating of the condition. Furthermore, treatment of preexisting melasma with retinoids and/or topical steroid may also result in erythema and telangiectasias. 
Wood's lamp examination and ultraviolet light photography are noninvasive techniques for differentiating melasma and EO but have not provided promising results as the two conditions can co-exist. 
Charlín et al.  and Sandra et al.  demonstrated in dermoscopy of patients with EO, dark brown globules and globular-like structures on a diffuse brown background. In contrast, in patients with melasma a fine brown reticular pattern on a background of a faint light brown, structure-less area was noted. However, the problem is these two conditions can co-exist. Dermoscopic differential diagnosis also included nevus of ota. 
Hence, it was not worthwhile to entirely rely on dermoscopy for the diagnosis of EO.
Gil et al.  further suggested the superiority of reflectance confocal microscopy as an emerging noninvasive tool in the diagnosis of EO. They demonstrated the presence of hyporefractile oval-to-banana-shaped spaces in the dermis which corresponded to the banana-shaped bodies on histopathology.
Histopathology, although invasive, remains a gold standard in the diagnosis of EO, and confirms it beyond doubt. The pathognomic histopathological feature is the presence of the ochre-colored, banana-shaped fibers in the dermis. Homogenization and swelling of collagen bundles in the papillary and reticular dermis may also be seen , [Figure 5] and [Figure 6]. Speckled macular lesions or early caviar-like papules are preferred lesions for a skin biopsy to yield more accuracy.
| Treatment|| |
EO has remained a very difficult condition to treat. Despite several modalities of treatments available, the results are often inconsistent, unpredictable and are often far from gratifying.
There are various modalities available for treatment as follows.
Most important step is to stop the further use of the offending agent. Avid sun-protection is said to be a help in the prevention of further progress of the condition to some extent. Wide-brim hats, sun-goggles and appropriate sun-protective clothing are equally important.
Physical sunblocks and chemical sunscreens widely help in clinical improvement of the skin lesions of EO, especially when combined with the other pharmacological and procedural approaches. , Topical retinoid acid, glycolic acid, and a topical corticosteroid (low-potency creams) used judiciously often lead to considerable improvement in pigmentation.  A solitary case report suggested the efficacy of tetracycline in the clearance of papular sarcoid-like ochronosis.  Antioxidants, high doses of Vitamin E and C, may assist dilution of the pigment. Both Vitamin C and Vitamin E act as de-pigmentating agents. Both act synergistically along with antioxidants to provide photoprotection. 
Chemical peeling with glycolic acid or tricarboxylic acid has been used for the treatment of EO shows improvement in pigmentation.  Few patients were treated with derma-abrasion. , One case report mentions combination treatment of derma-abrasion and CO 2 laser showing improvement. 
In one study done, two patients with EO were treated with a Q-switched 755-nm alexandrite laser at fluence of 6-8 J/cm 2 showed progressive lightening of pigmentation of the lesional skin and decreased dermal pigmentation on histological examination.  Q-switched alexandrite laser is believed to enhance the clearance of ochronotic pigment fibers from dermis. The Q-switched ruby laser was also used in another study which showed improvement. Kramer et al.  treated EO in a Hispanic woman with Q-switched 1064-nm neodymium-doped yttrium aluminium garnet (Nd: YAG) laser with satisfactory results. In another study, histologically proven cases of EO were treated with Q-switched Nd: YAG laser which showed satisfactory improvement in dyschromia. 
| Safety of Hydroquinone as Used in Cosmetics|| |
Information about safety and efficacy of hydroquinone indicates that it is absorbed dermally in both aqueous and alcoholic form. Its excretion is through glucuronide or sulfate conjugates. When assessed in animals, it was found to alter immune function both in vivo and in vitro and was associated with increased incidence of renal tubular cell tumors and leukemia. Quantitatively, the use of hydroquinone in cosmetics is unlikely to cause renal tubular cell tumor. Therefore, it is safe to use hydroquinone in nail adhesives and hair dyes at a concentration of ≤1%. It should not be used in other leave-on cosmetics. 
To summarize, EO is an underdiagnosed clinical entity, and its diagnosis is frequently missed in clinical practice. It is common in dark-skinned individuals and is increasingly being reported even in the fair-skinned individuals. Hydroquinone containing topical depigmenting agents is the leading cause of EO, especially when used for longer duration. Despite wide variety of treatment options available, treatment of EO is still unsatisfactory. The success of treatment is elusive even to the best therapeutic hands and is, therefore, remains a challenge to dermatologists. Hence, it is essential that the condition is suspected at an appropriate time, which might lead to the cessation of the progress of the condition.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Longo N. Inherited disorders of amino acid metabolism presenting in adults. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison′s Principles of Internal Medicine. 15 th
ed. New York: McGraw Hill; 2001. p. 2307.
Fisher AA, Davis MW. Alkaptonuric ochronosis with aortic valve and joint replacements and femoral fracture: A case report and literature review. Clin Med Res 2004;2:209-15.
Laskar FH, Sargison KD. Ochronotic arthropathy. J Bone Joint Surg 1970;52:653-66.
Tharini G, Ravindran V, Hema N, Prabhavathy D, Parveen B. Alkaptonuria. Indian J Dermatol 2011;56:194-6.
Vasudevan B, Sawhney MP, Radhakrishnan S. Alkaptonuria associated with degenerative collagenous palmar plaques. Indian J Dermatol 2009;54:299-301.
Koska L, Srsen S. A simple urine screening test for alcaptonuria. N Engl J Med 1977;297:1471-2.
Findlay GH, Morrison JG, Simson IW. Exogenous ochronosis and pigmented colloid milium from hydroquinone bleaching creams. Br J Dermatol 1975;93:613-22.
Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am J Clin Dermatol 2001;2:213-7.
Bruce S, Tschen JA, Chow D. Exogenous ochronosis resulting from quinine injections. J Am Acad Dermatol 1986;15 (2 Pt 2):357-61.
Dupré A, Bonafé JL, Viraben R, Arquie MT. Idiopathic pigmentation of the hands. Professional exogenous ochronosis? A new entity? Arch Dermatol Res 1979;266:1-9.
Virchow R. Ein fall von allegemeiner ochronose der knorpel aud knorpelahnlichen theile. Virchows Arch Pathol Anat 1866;37:212-9.
Pick L. Uber die Ochronose. Klin Wochenschr 1906;43:478-80.
Beddard AP, Plumtre CM. A further note on ochronosis associated with carboluria. Q J Med 1912;5:505-7.
Findlay GH, de Beer HA. Chronic hydroquinone poisoning of the skin from skin-lightening cosmetics. A South African epidemic of ochronosis of the face in dark-skinned individuals. S Afr Med J 1980;57:187-90.
Weiss RM, del Fabbro E, Kolisang P. Cosmetic ochronosis caused by bleaching creams containing 2% hydroquinone. S Afr Med J 1990;77:373.
Bentley-Phillips B, Bayles MA. Cutaneous reactions to topical application of hydroquinone. Results of a 6-year investigation. S Afr Med J 1975;49:1391-5.
DeCaprio AP. The toxicology of hydroquinone - Relevance to occupational and environmental exposure. Crit Rev Toxicol 1999;29:283-330.
Phillips JI, Isaacson C, Carman H. Ochronosis in black South Africans who used skin lighteners. Am J Dermatopathol 1986;8:14-21.
Dogliotti M, Leibowitz M. Granulomatous ochronosis - A cosmetic-induced skin disorder in blacks. S Afr Med J 1979;56:757-60.
Kramer KE, Lopez A, Stefanato CM, Phillips TJ. Exogenous ochronosis. J Am Acad Dermatol 2000;42(5 Pt 2):869-71.
Gil I, Segura S, Martínez-Escala E, Lloreta J, Puig S, Vélez M, et al.
Dermoscopic and reflectance confocal microscopic features of exogenous ochronosis. Arch Dermatol 2010;146:1021-5.
Snider RL, Thiers BH. Exogenous ochronosis. J Am Acad Dermatol 1993;28:662-4.
Levitt J. The safety of hydroquinone: A dermatologist′s response to the 2006 Federal Register. J Am Acad Dermatol 2007;57:854-72.
Zawar VP, Mhaskar ST. Exogenous ochronosis following hydroquinone for melasma. J Cosmet Dermatol 2004;3:234-6.
Zawar V, Chuh A. Exogenous ochronosis in Asians. Int J Dermatol 2010;49:101.
Gandhi V, Verma P, Naik G. Exogenous ochronosis after prolonged use of topical hydroquinone (2%) in a 50-year-old Indian female. Indian J Dermatol 2012;57:394-5.
Jain A, Pai SB, Shenoi SD. Exogenous ochronosis. Indian J Dermatol Venereol Leprol 2013;79:522-3.
Tan SK. Exogenous ochronosis in ethnic Chinese Asians: A clinicopathological study, diagnosis and treatment. J Eur Acad Dermatol Venereol 2011;25:842-50.
Kullavanijaya P, Ophaswongse S, Silprachawong S. Exogenous ochronosis and pigmented colloid milium induced by bleaching skin cream. Environ Dermatol 1998;5:20-5.
Tan SK. Exogenous ochronosis - A diagnostic challenge. J Cosmet Dermatol 2010;9:313-7.
Kadurina M, Dimitrov B, Tonev S. Hydroquinone-induced exogenous ochronosis. J Plast Dermatol 2009;5:197-201.
Hull PR, Procter PR. The melanocyte: An essential link in hydroquinone-induced ochronosis. J Am Acad Dermatol 1990;22:529-31.
Martins VM, Sousa AR, Portela Nde C, Tigre CA, Gonçalves LM, Castro Filho RJ. Exogenous ochronosis: Case report and literature review. An Bras Dermatol 2012;87:633-6.
Cullison D, Abele DC, O′Quinn JL. Localized exogenous ochronosis. J Am Acad Dermatol 1983;8:882-9.
Engasser PG. Ochronosis caused by bleaching creams. J Am Acad Dermatol 1984;10:1072-3.
Penneys NS. Ochronosislike pigmentation from hydroquinone bleaching creams. Arch Dermatol 1985;121:1239-40.
O′Donoghue MN, Lynfield YL, Derbes V. Ochronosis due to hydroquinone. J Am Acad Dermatol 1983;8:123.
Jordaan HF, Van Niekerk DJ. Transepidermal elimination in exogenous ochronosis. A report of two cases. Am J Dermatopathol 1991;13:418-24.
Diven DG, Smith EB, Pupo RA, Lee M. Hydroquinone-induced localized exogenous ochronosis treated with dermabrasion and CO2 laser. J Dermatol Surg Oncol 1990;16:1018-22.
Hardwick N, Van Gelder LW, Van der Merwe CA, Van der Merwe MP. Exogenous ochronosis: An epidemiological study. Br J Dermatol 1989;120:229-38.
Zawar V, Tan SK. Exogenous ochronosis: A review for clinicians. Expert Rev Dermatol 2012;7:171-80.
Charlín R, Barcaui CB, Kac BK, Soares DB, Rabello-Fonseca R, Azulay-Abulafia L. Hydroquinone-induced exogenous ochronosis: A report of four cases and usefulness of dermoscopy. Int J Dermatol 2008;47:19-23.
Romero SA, Pereira PM, Mariano AV, Francesconi F, Francesconi VA. Use of dermoscopy for diagnosis of exogenous ochronosis. An Bras Dermatol 2011;86(Suppl 1):S31-4.
Williams H. Skin lightening creams containing hydroquinone. BMJ 1992;305:903-4.
Fisher AA. Tetracycline treatment for sarcoid-like ochronosis due to hydroquinone. Cutis 1988;42:19-20.
Burke KE. Interaction of Vitamins C and E as better cosmeceuticals. Dermatol Ther 2007;20:314-21.
Lang PG Jr. Probable coexisting exogenous ochronosis and mercurial pigmentation managed by dermabrasion. J Am Acad Dermatol 1988;19(5 Pt 2):942-6.
Bellew SG, Alster TS. Treatment of exogenous ochronosis with a Q-switched alexandrite (755 nm) laser. Dermatol Surg 2004;30(4 Pt 1):555-8.
Tan SK. Exogenous ochronosis - Successful outcome after treatment with Q-switched Nd: YAG laser. J Cosmet Laser Ther 2013;15:274-8.
Andersen FA, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, et al.
Final amended safety assessment of hydroquinone as used in cosmetics. Int J Toxicol 2010;29 6 Suppl: 274S-87.
What is new?
- Reflectance confocal microscopy as an emerging noninvasive tool in the diagnosis of EO
- Q switch Nd Yag laser may be useful in certain patients of EO, those not responsive to medical line of therapy
- Dermatologist′s supervision during hydroquinone treatment is important to early diagnosis and prevention of EO
- Hydroquinone content in cosmetics should be less than 1%
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6]
| Article Access Statistics|
| Viewed||8311 |
| Printed||101 |
| Emailed||6 |
| PDF Downloaded||429 |
| Comments ||[Add] |